Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E.
Target Price
The average target price of SABS is 9.1 and suggests 114% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell